U.S. market Closed. Opens in 4 hours

GHSI | Guardion Health Sciences, Inc. Stock Overview

(Stock Exchange: NASDAQ)
Day's Range 3.22 - 3.22
52 Week Range 3.04 - 18.00
Beta N/A
Implied Volatility N/A
IV Rank N/A
Day's Volume 664
Average Volume 121,228
Shares Outstanding 1,349,960
Market Cap 4,346,871
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
IPO Date 2019-04-05
Valuation
Profitability
Growth
Health
P/E Ratio -0.78
Forward P/E Ratio N/A
EPS -4.11
1YR Price Target N/A
Dividend Yield 615.38%
Dividend Per Share 19.82
Dividend ExDate N/A
Dividend PayDate N/A
Employees 9
Country USA
Website GHSI
Guardion Health Sciences, Inc., together with its subsidiaries, operates as a specialty health sciences company in the United States. It operates in two segments, Medical Foods and Nutraceuticals, and Medical Devices. The company offers Lumega-Z, a medical food that replenishes and restores the macular protective pigment; and GlaucoCetin, a vision-specific medical food to support and protect the mitochondrial function of optic nerve cells, as well as improve blood flow in the ophthalmic artery in patients with glaucoma. It also provides MapcatSF, a medical device that measures the macular pigment optical density; CSV-1000 device that offers auto-calibrated tests to ensure the correct testing luminance and contrast levels; and CSV-2000, a digital standardized contrast sensitivity testing device, as well as develops, manufactures, and sells equipment and supplies for standardized vision testing under the VectorVision name for use by eye doctors in clinical trials, real-world vision evaluation, and industrial vision testing. In addition, the company develops ImmuneSF, a nutraceutical formulation, as well as a portfolio of nutraceutical products under the NutriGuard brand. Further, it distributes medical foods products through e-commerce in an online store, guardionhealth.com. Guardion Health Sciences, Inc. was founded in 2009 and is headquartered in San Diego, California.
*Chart delayed
Analyzing fundamentals for GHSI we got that it has weak fundamentals where Valuation is considered to be overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is very weak. For more detailed analysis please see GHSI Fundamentals page.

Watching at GHSI technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on GHSI Technicals page.
An error has occurred. This application may no longer respond until reloaded. Reload 🗙